{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-037916","form_type":"8-K","ticker":"DNA","cik":"0001830214","company_name":"Ginkgo Bioworks Holdings, Inc.","filed_at":"2023-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.837927+00:00","generated_at":"2026-06-08T10:37:40.691405+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Ginkgo Q3 2023: Total revenue $55M (-17% YoY); Cell Engineering up 51%; revises FY23 outlook","bullets":["Cell Engineering revenue $37M (+51% YoY); Biosecurity revenue $18M with 62% gross margin.","Loss from ops $(286)M including $96M impairment charge; Adj. EBITDA $(84)M vs $(72)M prior year.","Added 21 new Cell Programs in Q3, 40% growth YoY; full-year target revised to 80-85 programs.","New partnerships: Pfizer RNA drug discovery (up to $331M milestones) and Google Cloud AI deal.","FY23 revenue guidance cut to $250-260M; Cell Engineering $145-150M; Biosecurity up to $110M."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-037916","json":"https://secwatch.observer/filing/0001628280-23-037916.json","markdown":"https://secwatch.observer/filing/0001628280-23-037916.md","text":"https://secwatch.observer/filing/0001628280-23-037916.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1830214/000162828023037916/0001628280-23-037916-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1830214/000162828023037916/dna-20231108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T10:37:40.691405+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4da8a1b135228c1152e83a898513fff9ea54b452","claim":"Ginkgo Bioworks Holdings, Inc. reported third quarter ended September 30, 2023 results: revenue $55 million, net income $(286) million. Guidance lowered.","evidence_excerpt":"of next-generation biological intelligence capabilities, including AI-based epidemic forecasting Third Quarter 2023 Financial Highlights • Third quarter 2023 Total revenue of $55 million, down from $66 million in the comparable prior year period, a decrease of 17% primarily driven by the expected ramp down of K-12 testing in Ginkgo’s Biosecurity segment • Third","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1830214/000162828023037916/0001628280-23-037916-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2023"},{"label":"Revenue","value":"$55 million"},{"label":"Net income","value":"$(286) million"},{"label":"Guidance","value":"lowered"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}